Immuron partners with Calmino to distribute ProIBS in Australia, New Zealand

Immuron (IMRN) is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS will join Immuron’s product portfolio which includes the rapidly growing Travelan brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend. Tobias Kisker, CEO and founder of Calmino group AB, is pleased to start a long and successful collaboration with Immuron. “The Calmino team is happy to work with a well-established, experienced, and professional company like Immuron. We see Australia and New Zealand as important Asian Pacific markets with significant potential.”